MarginsXMarginsX
Home › Markets › Health Care › BCRX

BioCryst Pharmaceuticals Inc. (BCRX)

BCRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.45
-2.10% on the day
Market cap
$1.9B
Small cap
Revenue · 2025
$874.8M
+94.1% on 2024
Net income · 2025
$263.9M
30.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/882796/000162828026012240/0001628280-26-012240-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBCRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year1994
SEC CIK0000882796

Financials · 2025

LineValue
Revenue$874.8M
Net income$263.9M
Operating income$341.0M
Net margin30.2%
Operating margin39.0%
Revenue growth+94.1%
Cash$89.7M
Total assets$514.2M
P/E (computed)7.3×
P/S (computed)2.2×

Warning signs

Cash runway
Cash-flow positive
$97.0M cash at September 30, 2026
Share count, 1 year
+22.2%
2025-10-31 to 2026-10-30 · +25.6% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$4.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$97.0M cash; operating cash flow $91.9M a quarter.Report 2026-09-30
Shares outstanding257,299,269 (2026-10-30); 210,543,224 a year earlier; 204,809,380 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Raleigh, North Carolina, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$180.3M$37.9M$33.0M$97.0M$395.6M$961.5M10-Q 2026-11-04
Q2 2026
2026-06-30
$218.3M$78.4M$104.3M$155.0M$395.4M$940.6M10-Q 2026-08-05
Q1 2026
2026-03-31
$156.4M-$721.8M-$61.8M$171.6M$395.2M$885.7M10-Q 2026-05-06
Q4 2025
2025-12-31
$406.6M$245.8M$292.0M$89.7M$0$874.8M10-K 2026-02-26
Q3 2025
2025-09-30
$159.4M$12.9M$41.6M$84.1M$194.4M$599.8M10-Q 2026-11-04
Q2 2025
2025-06-30
$163.4M$5.1M$41.3M$88.0M$242.8M$557.5M10-Q 2026-08-05
Q1 2025
2025-03-31
$145.5M$32K-$27.5M$105.2M$315.4M$503.5M10-Q 2026-05-06
Q4 2024
2024-12-31
$131.5M-$26.8M-$5.2M$104.7M$314.9M$450.7M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-1.0%
1 month-5.7%
3 months-22.4%
Year to date-2.4%
1 year+10.3%
From 52-week high-31.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
REPLReplimune Group Inc.$21.41-2.19%$2.0B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
ALVOAlvotech$4.41+5.13%$1.7B
BEAMBeam Therapeutics Inc.$20.94-8.28%$2.2B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier